Survodutide

Metabolic & weight Investigational (in clinical trials)

Glucagon/GLP-1 dual receptor agonist · also known as BI 456906

For reference only — not medical advice. Figures are commonly reported values compiled from published sources and may be wrong or out of date. Many compounds listed are not approved for human use. Talk to a licensed clinician before using any compound.

Survodutide, from Boehringer Ingelheim with Zealand Pharma, pairs GLP-1 receptor activity with glucagon receptor activity. A 46-week phase 2 trial in adults with overweight or obesity reported dose-dependent weight loss, and phase 3 SYNCHRONIZE results were announced in 2026. It has also received breakthrough designation in the US for MASH with fibrosis, but it is not an approved medicine.

Commonly reported dosing (10 mg vial)

Reconstituted with 2 mL → 5 mg/mL.

Phase	Dose	Volume	U-100 units
Starting	600 mcg	0.12 mL	12
Standard	3.6 mg	0.72 mL	72

Frequency: Once weekly, subcutaneous · Half-life: Long-acting; studied as a once-weekly injection

Open in calculator

Commonly reported dose escalation

Weeks	Dose	Volume	U-100 units
Weeks 1-2	600 mcg	0.12 mL	12
Weeks 3-4	1.2 mg	0.24 mL	24
Weeks 5-6	1.8 mg	0.36 mL	36
Weeks 7-8	2.4 mg	0.48 mL	48
Weeks 9-10	3.6 mg	0.72 mL	72
Weeks 11-12	4.8 mg	0.96 mL	96
Week 13+	6 mg	1.2 mL	120 (warning)

⚠ More than the vial contains or more than a 1 mL syringe holds at this concentration — a larger vial or different reconstitution would be needed.

Higher steps may need a larger vial or more than one draw. Escalation schedules vary; dosing decisions belong to a licensed clinician.

Commonly reported reconstitution steps

Vials are usually brought to room temperature (about 15-20 minutes) first.
2 mL of bacteriostatic water is added slowly down the inside wall of the 10 mg vial.
The vial is swirled gently until clear, not shaken.
This gives 5 mg/mL. Mixed vials are typically labeled with the date and refrigerated.

Storage

Before mixing: Lyophilized vials are commonly stored frozen (around -20 °C) and protected from light.

After mixing: Reconstituted solution is commonly kept refrigerated (2-8 °C), protected from light, and not frozen. Repeated freeze-thaw cycles are commonly avoided.

How it works

GLP-1 receptor activation reduces appetite and slows gastric emptying, while glucagon receptor activation is thought to raise energy expenditure and reduce liver fat.

Researched for

Phase 2 dose-finding trial in obesity (0.6 to 4.8 mg once weekly for 46 weeks).
Phase 2 trial in MASH with fibrosis and the phase 3 SYNCHRONIZE programme (3.6 mg and 6.0 mg) in obesity.

Notes

The escalation shown mirrors a community chart that reaches 6 mg by week 13; the phase 2 trial escalated more slowly, over 20 weeks.
The 6 mg phase 3 step (shown in the escalation table) is 1.2 mL at 2 mL reconstitution, which exceeds a 1 mL syringe and is reported as split draws.
Gastrointestinal events were the most frequent adverse events in trials.